Figure 1 - uploaded by Maite Rivera Gorrin
Content may be subject to copyright.
Citations
... Mit einer Phototherapie in Form von NB-UVB und PUVA können Juckreiz und Hautläsionen möglicherweise wirksam kontrolliert werden [ 3, 12,27,47,48 ] . Eine Behandlung durch Phototherapie wurde in insgesamt 20 Fallberichten beschrieben: Bade-PUVA-Therapie bei einem Patienten [ 48 ] , Creme-PUVA-Therapie ebenfalls bei einem Patienten [ 36 ] und NB-UVB bei weiteren 18 Patienten [ 3, 11,12,14,27,31,[49][50][51][52][53][54][55][56][57][58][59][60] . Bei den meisten dieser Fälle wurde eine UVB-Phototherapie nach einer wirkungslosen Behandlung mit topischen Steroiden und Antihistaminika angewendet, wobei sich eine Verbesserung der Symptome beobachten ließ. ...
... Phototherapy in the form of NB-UVB and PUVA may be effective in controlling pruritus and skin lesions [3,12,27,47,48]. Altogether, 20 case reports described treatment with phototherapy: one case with bath PUVA [48], one case with cream PUVA [36], and 18 case reports with NB-UVB [3,11,12,14,27,31,[49][50][51][52][53][54][55][56][57][58][59][60]. In most of these cases, UVB phototherapy was used after ineffective therapy with topical steroids and antihistamines, with reported improvement. ...
Reactive perforating dermatosis is a rare chronic skin disease defined by the transepidermal elimination of collagen and/or elastin. In the acquired form in adults, it is frequently associated with diseases such as diabetes and chronic renal failure. No systematic reviews of treatment options are available for this disease. The aim of this systematic review is to summarize all reported treatment options for acquired reactive perforating dermatosis (ARPD). This is a systematic review based on a MEDLINE search of articles in English and German from 1990 to 2016.
Most medical literature on the treatment of ARPD is limited to individual case reports and small series of patients. Various therapies that have been tried include antihistamines, topical keratolytics, corticosteroids, tretinoin, oral drugs such as allopurinol or antibiotics, and phototherapy or photochemotherapy.
While there are no specific criteria for the evidence‐based selection of treatment options for ARPD, the first priority in management of these conditions should be treatment of an underlying disease if present. None of the described modalities has been approved for first‐line therapy. It is recommended to choose a combination of drugs that reduce itching and assist in the resolution of the skin lesions at the same time.
... Very limited information is available about APD in the PD population [4,5,9,10]. There have been known cases of APD in the PD population, as seen in the literature from Saray, and Morton et al., but there have been no direct studies comparing HD and PD populations. ...
Acquired perforating dermatosis (APD) is a debilitating and itchy skin disease. Its diagnosis is based on biopsy and the treatment is not very clear. It is not well established as to how wide spread it is in patients on peritoneal dialysis (PD) and its implications in this population have not been well studied. Here we present a case of APD that developed in a patient on PD. Its pathology and treatment options are reviewed. More studies are needed to assess the prevalence of APD in PD population.
